Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease-Reference-Cited by-同舟云学术

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

Published:2014-01 Issue:1 Volume:113 Page:76-83
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Gotto Antonio M.,Cannon Christopher P.,Li Xiujiang Susie,Vaidya Sanskruti,Kher Uma,Brinton Eliot A.,Davidson Michael,Moon Jennifer E.,Shah Sukrut,Dansky Hayes M.,Mitchel Yale,Barter Philip

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference11 articles.

1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Lancet,2010

2. Statins for the primary prevention of cardiovascular disease;Taylor;Cochrane Database Syst Rev,2011

3. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events;Barter;N Engl J Med,2007

4. Safety of anacetrapib in patients with or at high risk for coronary heart disease;Cannon;N Engl J Med,2010

5. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib;Davidson;J Lipid Res,2013

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitation of anacetrapib in human and animal adipose by liquid chromatography with mass spectrometric detection;Bioanalysis;2024-08-09

2. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis;Journal of Cardiovascular Development and Disease;2024-05-16

3. New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?;Expert Opinion on Therapeutic Targets;2024-05-03

4. Evolving Therapeutic Targets;Clinical Lipidology;2024

5. Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments;Current Atherosclerosis Reports;2023-12-22